DE60325354D1 - Topisch anwendbare pharmazeutische zubereitung - Google Patents

Topisch anwendbare pharmazeutische zubereitung

Info

Publication number
DE60325354D1
DE60325354D1 DE60325354T DE60325354T DE60325354D1 DE 60325354 D1 DE60325354 D1 DE 60325354D1 DE 60325354 T DE60325354 T DE 60325354T DE 60325354 T DE60325354 T DE 60325354T DE 60325354 D1 DE60325354 D1 DE 60325354D1
Authority
DE
Germany
Prior art keywords
pharmaceutical preparation
topic
applicable pharmaceutical
applicable
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325354T
Other languages
English (en)
Inventor
Christina Bolle
Rudolf Linder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Application granted granted Critical
Publication of DE60325354D1 publication Critical patent/DE60325354D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/12—Crossbows
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/12—Crossbows
    • F41B5/123—Compound crossbows
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/14—Details of bows; Accessories for arc shooting
    • F41B5/1442—Accessories for arc or bow shooting
    • F41B5/1469—Bow-string drawing or releasing devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60325354T 2002-05-28 2003-05-27 Topisch anwendbare pharmazeutische zubereitung Expired - Lifetime DE60325354D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP02011830 2002-05-28
DE10223828 2002-05-28
DE10311613 2003-03-14
PCT/EP2003/005524 WO2003099334A1 (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation

Publications (1)

Publication Number Publication Date
DE60325354D1 true DE60325354D1 (de) 2009-01-29

Family

ID=29587313

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60334692T Expired - Lifetime DE60334692D1 (de) 2002-05-28 2003-05-27 Ophthalmologische zubereitung enthaltend roflumilast in der behandlung von krankheiten der augen
DE60325354T Expired - Lifetime DE60325354D1 (de) 2002-05-28 2003-05-27 Topisch anwendbare pharmazeutische zubereitung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60334692T Expired - Lifetime DE60334692D1 (de) 2002-05-28 2003-05-27 Ophthalmologische zubereitung enthaltend roflumilast in der behandlung von krankheiten der augen

Country Status (33)

Country Link
US (7) US20060084684A1 (de)
EP (3) EP1511516B1 (de)
JP (3) JP2005529928A (de)
KR (2) KR101307093B1 (de)
CN (3) CN101491520B (de)
AT (2) ATE485821T1 (de)
AU (2) AU2003232828B2 (de)
BR (2) BR0311337A (de)
CA (2) CA2486910C (de)
CY (2) CY1110312T1 (de)
DE (2) DE60334692D1 (de)
DK (3) DK2020243T3 (de)
EA (2) EA010416B1 (de)
ES (3) ES2319517T3 (de)
HK (2) HK1079437A1 (de)
HR (1) HRP20041211B1 (de)
HU (1) HUE039709T2 (de)
IL (3) IL164935A (de)
IS (1) IS2639B (de)
LT (1) LT2020243T (de)
MA (1) MA27813A1 (de)
ME (1) ME00565A (de)
MX (2) MXPA04011528A (de)
NO (2) NO334882B1 (de)
NZ (3) NZ553731A (de)
PL (3) PL397021A1 (de)
PT (3) PT1511481E (de)
RS (1) RS51104B (de)
SI (2) SI2020243T1 (de)
TR (1) TR201815573T4 (de)
UA (2) UA88523C2 (de)
WO (2) WO2003099278A1 (de)
ZA (2) ZA200408649B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
ATE485821T1 (de) * 2002-05-28 2010-11-15 Nycomed Gmbh Ophthalmologische zubereitung enthaltend roflumilast in der behandlung von krankheiten der augen
MXPA05003063A (es) 2002-09-20 2005-05-27 Alcon Inc Uso de inhibidores de la sintesis de citosina para el tratamiento de trastornos de ojos secos.
FR2851247B1 (fr) * 2003-02-19 2007-06-29 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de pathologies degeneratives oculaires
PT1606261E (pt) 2003-03-10 2010-01-11 Nycomed Gmbh Novo processo para a preparação de roflumilast
US20070082017A1 (en) * 2004-01-10 2007-04-12 Tseng Scheffer C Lipid compositions and methods of use
DE102004046235A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
DE102004046236A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
CN102600144A (zh) * 2005-03-08 2012-07-25 奈科明有限责任公司 治疗糖尿病的罗氟司特
CA2601250C (en) * 2005-03-16 2014-10-28 Nycomed Gmbh Taste masked dosage form containing roflumilast
CA2610881A1 (en) * 2005-06-09 2006-12-14 Santen Pharmaceutical Co., Ltd. Eye drop containing roflumilast
CN101389612B (zh) 2006-02-21 2011-09-21 卫材R&D管理有限公司 喹唑啉衍生物
AU2008215411B2 (en) 2007-02-16 2012-11-22 Eisai R & D Management Co., Ltd. Crystal, amorphous form and salt of methyl N-[3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid
JP5043945B2 (ja) 2007-08-17 2012-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナゾリン誘導体の製造方法
TWI414296B (zh) 2007-08-17 2013-11-11 Eisai R&D Man Co Ltd Innovative agents
IN2012DN03631A (de) 2009-10-30 2015-06-26 Nestec Sa
ES2408132B1 (es) * 2010-09-08 2014-04-04 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento de la epífora.
ES2377785B2 (es) 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.
US9387195B2 (en) 2011-03-07 2016-07-12 Celgene Corporation Methods for treating diseases using isoindoline compounds
CN102793684B (zh) * 2011-05-26 2016-02-17 杭州赛利药物研究所有限公司 罗氟司特液体制剂及其制备方法
CU24163B1 (es) * 2011-06-28 2016-03-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
EP2836240B1 (de) * 2012-04-10 2019-03-13 Georgia State University Research Foundation, Inc. Zusammensetzungen und verfahren zur behandlung von mittelohrentzündung und anderen erkrankungen mit cyld-inhibitoren
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103570610B (zh) * 2012-07-18 2017-08-11 重庆华邦制药有限公司 一种罗氟司特微粒的制备方法
EA035391B1 (ru) * 2012-11-08 2020-06-05 Ризен Фармасьютикалз Са Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы
ES2888074T3 (es) 2013-08-16 2021-12-30 Univ Maastricht Tratamiento del deterioro cognitivo con inhibidor de PDE4
CN105434328A (zh) * 2014-09-01 2016-03-30 天津药物研究院有限公司 一种含罗氟司特固体分散体的固体制剂及其制备方法
JP5938537B1 (ja) * 2014-10-24 2016-06-22 久光製薬株式会社 プロドラッグ
CN104997959A (zh) * 2015-08-21 2015-10-28 蔡宇平 一种用于治疗睑板腺囊肿的中药
CN106148528B (zh) * 2016-07-11 2019-10-01 赵晨 一种遗传性Usher综合征的致病突变及其检测试剂
US20200155524A1 (en) * 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN108283620A (zh) * 2018-03-13 2018-07-17 兆科药业（广州）有限公司 一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法
JP7492918B2 (ja) * 2018-06-04 2024-05-30 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物
KR102117525B1 (ko) * 2018-07-09 2020-06-01 건양대학교 산학협력단 Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물
CN115551478A (zh) 2020-01-31 2022-12-30 阿尔库缇斯生物疗法股份有限公司 具有改善递送和血浆半衰期的罗氟司特局部制剂
CN114641297A (zh) * 2020-05-07 2022-06-17 阿尔库缇斯生物疗法股份有限公司 使用高克拉夫特温度阴离子表面活性剂治疗皮肤病症
WO2022169615A1 (en) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
EP4291162A1 (de) * 2021-02-10 2023-12-20 Iolyx Therapeutics, Inc. Verfahren zur ophthalmischen verabreichung von roflumilast
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
EP4351612A2 (de) * 2021-06-01 2024-04-17 Eyedea Bio, Llc System zur verabreichung von arzneimitteln mit verlängerter freisetzung für augenarzneimittel und verfahren zur verwendung
IL311534A (en) * 2021-09-22 2024-05-01 Iolyx Therapeutics Inc Methods for treating ocular inflammatory diseases
US20240108609A1 (en) 2022-09-15 2024-04-04 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US5011843A (en) * 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
US5891904A (en) * 1992-09-14 1999-04-06 Wolf-Georg Forssmann Use of inhibitors of phosphodiesterase IV
CN1046939C (zh) * 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
US5747069A (en) * 1993-08-10 1998-05-05 Fujisawa Pharmaceutical Co., Ltd. Percutaneously absorbable preparation
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
AU5758199A (en) * 1998-09-29 2000-04-17 Fujisawa Pharmaceutical Co., Ltd. Novel salts of pyridopyrazine compound and crystals thereof
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US20020006418A1 (en) * 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
SI1161239T1 (en) 1999-03-10 2005-06-30 Altana Pharma Ag 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
TR200201150T2 (tr) * 1999-10-29 2002-09-23 Smithkline Beecham Corporation Bir fosfodiesteraz 4 inhibitörünün uygulanmasına dair metod.
JP2003522165A (ja) * 2000-01-31 2003-07-22 ファイザー・プロダクツ・インク Ｐｄｅ４アイソザイムの阻害剤として有用なピリミジンカルボキサミド
AU2001238288A1 (en) * 2000-02-16 2001-08-27 University Of Nebraska Medical Center Method and compositions for treating fibrotic diseases
AU6196201A (en) * 2000-05-25 2001-12-03 Merck Frosst Canada Inc Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
AU2002227123A1 (en) * 2000-11-07 2002-05-21 Merck And Co., Inc. Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) * 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US20030092706A1 (en) * 2001-11-09 2003-05-15 Johannes Barsig Combination
ATE485821T1 (de) * 2002-05-28 2010-11-15 Nycomed Gmbh Ophthalmologische zubereitung enthaltend roflumilast in der behandlung von krankheiten der augen

Also Published As

Publication number Publication date
NZ536920A (en) 2007-04-27
CN1655782A (zh) 2005-08-17
HK1079437A1 (en) 2006-04-07
ME00565A (en) 2011-12-20
JP5652983B2 (ja) 2015-01-14
EA010416B1 (ru) 2008-08-29
WO2003099278A1 (en) 2003-12-04
JP2012229245A (ja) 2012-11-22
MA27813A1 (fr) 2006-04-03
CA2486910A1 (en) 2003-12-04
NZ553731A (en) 2007-07-27
ATE485821T1 (de) 2010-11-15
US20140303215A1 (en) 2014-10-09
CN101491520A (zh) 2009-07-29
ES2693094T3 (es) 2018-12-07
ZA200409584B (en) 2006-05-31
US20210116207A1 (en) 2021-04-22
PT1511481E (pt) 2011-01-14
NO20045656L (no) 2004-12-27
HRP20041211A2 (hr) 2006-04-30
CN1655823B (zh) 2010-05-26
PL372082A1 (en) 2005-07-11
MXPA04011528A (es) 2005-02-14
RS101404A (en) 2007-02-05
AU2003232828B2 (en) 2010-06-24
NO20045506L (no) 2004-12-16
SI1511516T1 (sl) 2009-06-30
CN1655823A (zh) 2005-08-17
US20080280958A1 (en) 2008-11-13
PL397021A1 (pl) 2012-03-26
PT2020243T (pt) 2018-11-09
DK1511481T3 (da) 2011-01-24
NZ537308A (en) 2009-09-25
KR101307093B1 (ko) 2013-09-11
CA2486910C (en) 2011-11-29
BR0311339A (pt) 2005-03-22
CN100490804C (zh) 2009-05-27
US20060084684A1 (en) 2006-04-20
CN101491520B (zh) 2011-03-16
EP1511481B1 (de) 2010-10-27
JP2005529930A (ja) 2005-10-06
IL164935A0 (en) 2005-12-18
AU2003240719B2 (en) 2009-12-10
EA200702588A1 (ru) 2008-08-29
HRP20041211B1 (hr) 2013-06-30
EP1511481A1 (de) 2005-03-09
UA88523C2 (ru) 2009-10-26
EP2020243B1 (de) 2018-08-15
EP1511516B1 (de) 2008-12-17
AU2003232828A1 (en) 2003-12-12
IL209657A0 (en) 2011-02-28
KR20050014844A (ko) 2005-02-07
EP2020243A1 (de) 2009-02-04
CY1110312T1 (el) 2015-01-14
RS51104B (sr) 2010-10-31
IL165065A (en) 2010-11-30
NO334916B1 (no) 2014-07-14
PL212134B1 (pl) 2012-08-31
SI2020243T1 (sl) 2018-11-30
PL211870B1 (pl) 2012-07-31
EA020569B1 (ru) 2014-12-30
PT1511516E (pt) 2009-02-20
EA200401517A1 (ru) 2005-06-30
HUE039709T2 (hu) 2019-01-28
ES2319517T3 (es) 2009-05-08
US20060084685A1 (en) 2006-04-20
TR201815573T4 (tr) 2018-11-21
DE60334692D1 (de) 2010-12-09
EP1511516A1 (de) 2005-03-09
DK1511516T3 (da) 2009-04-06
US20190029956A1 (en) 2019-01-31
UA81910C2 (uk) 2008-02-25
LT2020243T (lt) 2018-11-12
ES2354971T3 (es) 2011-03-21
MXPA04011612A (es) 2005-03-07
KR20110122230A (ko) 2011-11-09
PL372095A1 (en) 2005-07-11
WO2003099334A1 (en) 2003-12-04
AU2003240719A1 (en) 2003-12-12
BR0311337A (pt) 2005-03-15
DK2020243T3 (en) 2018-11-19
US20110313005A1 (en) 2011-12-22
JP5683538B2 (ja) 2015-03-11
ATE417628T1 (de) 2009-01-15
IL164935A (en) 2010-12-30
JP2005529928A (ja) 2005-10-06
IS2639B (is) 2010-06-15
HK1079445A1 (en) 2006-04-07
IS7612A (is) 2004-12-23
NO334882B1 (no) 2014-06-30
CA2486917A1 (en) 2003-12-04
CA2486917C (en) 2011-11-22
CY1121133T1 (el) 2019-12-11
ZA200408649B (en) 2007-12-27
IL165065A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
CY1121133T1 (el) Τοπικα εφαρμοσιμο φαρμακευτικο παρασκευασμα
AU1708202A (en) Organic compounds
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
AU2002211863A1 (en) Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
ATE516017T1 (de) Feste pharmazeutische dosierform enthaltende ritonavir
ATE337016T1 (de) Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
ECSP045447A (es) Preparación farmacéutica que se puede aplicar por vía tópica
ITMI931104A1 (it) Preparazione di una forma farmaceutica atta a combattere l'iperinsulinismo

Legal Events

Date Code Title Description
8364 No opposition during term of opposition